  Genentech,  Inc. (South San Francisco, CA, 

),  has announced an agreement with Tercica, Inc. (South San Francisco, CA, 

), for the development,  manufacture, and commercialization of two products containing Genentech’s  recombinant human growth hormone Nutropin AQ (somatropin, rDNA origin) and  Tercica’s recombinant insulin-like growth factor-1 Increlex (mecasermin, rDNA  origin) for the treatment of short stature, adult growth hormone deficiency  (AGHD), and potentially other metabolic disorders.  

Under  the terms of the collaboration, Tercica may be eligible to receive a total of  up to $53 million in equity payments, opt-in payments, research and development  cost reimbursement, and milestone payments. Tercica will fund and lead initial  development efforts for both combination products. Genentech has certain rights  to opt-in to the development programs for both products. The opt-in rights  remain open until completion of a Phase 2 clinical study for each product that  is sufficient to enable a pivotal trial.

In  another deal, Genentech has formed a collaboration with Abbott (Abbott Park, IL, 

) for the global research,  development, and commercialization of ABT-263 and ABT-869, Abbott’s  investigational anticancer compounds. The companies will copromote any  resulting products in the US.  Abbott will promote any resulting products outside the United States.  Financial terms of the collaboration were not disclosed.

News

Genentech, Inc. (South San Francisco, CA, www.gene.com), has announced an agreement with Tercica, Inc. (South San Francisco, CA, www.tercica.com), for the development, manufacture, and commercialization of two products containing Genentech?s recombinant human growth hormone Nutropin AQ (somatropin, rDNA origin) and Tercica?s recombinant insulin-like growth factor-1 Increlex (mecasermin, rDNA origin) for the treatment of short stature, adult growth hormone deficiency (AGHD), and potentially other metabolic disorders.